Literature DB >> 11751067

Increased risk of osteoporotic fractures in patients with Cushing's syndrome.

Peter Vestergaard1, Jørgen Lindholm, Jens Otto L Jørgensen, Claus Hagen, Hans Christian Hoeck, Peter Laurberg, Lars Rejnmark, Kim Brixen, Lars Ø Kristensen, Ulla Feldt-Rasmussen, Leif Mosekilde.   

Abstract

OBJECTIVE: To evaluate if fracture risk was increased in patients with Cushing's syndrome due to the increased endogenous cortisol production.
DESIGN: Cohort.
METHODS: A self-administered questionnaire was mailed to 125 patients with Cushing's syndrome diagnosed between 1985 and 1999 in Denmark. The response of each patient was compared with that of three age- and gender-matched control subjects randomly drawn among respondents to the same questionnaire from the background population.
RESULTS: One hundred and four patients (83%) responded. The median age of the patients was 48 years (range 19-85 years). Sixty-eight had pituitary disease, 28 had adrenal disease, four had had both pituitary and adrenal surgery while four had not undergone surgery at the time of the study. The median time from diagnosis to surgery was 0.2 (range 0-3) years. Eighty-six percent were cured following surgery. There was an increased fracture risk within the last 2 years prior to diagnosis (incidence rate ratio 6.0, 95% confidence intervals (CI): 2.1-17.2). More than 2 years prior to diagnosis and following diagnosis there was no difference in fracture risk between patients and controls. The patients had more low-energy fractures than the controls (relative risk 5.4, 95% CI: 1.4-20.1). There was no difference in fracture risk between patients with adrenal or pituitary disease.
CONCLUSIONS: Patients with Cushing's syndrome had an increased fracture risk in a narrow time interval before diagnosis, while no increase in fracture risk could be demonstrated after diagnosis and treatment.

Entities:  

Mesh:

Year:  2002        PMID: 11751067     DOI: 10.1530/eje.0.1460051

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  29 in total

1.  Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study.

Authors:  Akiko Kawamata; Masatoshi Iihara; Takahiro Okamoto; Takao Obara
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 2.  Utility of the trabecular bone score (TBS) in secondary osteoporosis.

Authors:  Fabio M Ulivieri; Barbara C Silva; Francesco Sardanelli; Didier Hans; John P Bilezikian; Renata Caudarella
Journal:  Endocrine       Date:  2014-05-23       Impact factor: 3.633

3.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

4.  Cortisol Measures Across the Weight Spectrum.

Authors:  Melanie Schorr; Elizabeth A Lawson; Laura E Dichtel; Anne Klibanski; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

5.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

6.  Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.

Authors:  Gherardo Mazziotti; Anna Maria Formenti; Robert A Adler; John P Bilezikian; Ashley Grossman; Emilia Sbardella; Salvatore Minisola; Andrea Giustina
Journal:  Endocrine       Date:  2016-10-20       Impact factor: 3.633

7.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

8.  Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.

Authors:  Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov
Journal:  Osteoporos Int       Date:  2013-01-29       Impact factor: 4.507

9.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 10.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.